BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Policy

  Antengene Announces the Approval of First-in-Class Oral XPO1 Inhibitor Selinexor in South Korea for the Treatment of Relapsed or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma

  Antengene Corporation Limited announced that through a priority review process, the South Korean Ministry of Food and Drug Safety has approved the company’s NDA for the Orphan Drug-designated first-in-class oral inhibitor of XPO1.

  August 1, 2021

   · 

  5 min read
• Business

  GC Pharma and Tottori University Enter Research Collaboration and License Agreement for Development of GM1 Gangliosidosis Chaperone Therapy

  GC Pharma and Tottori University announced a worldwide licensing and collaboration agreement for the orally administrable chaperone drug of GM1 gangliosidosis.

  August 1, 2021

   · 

  4 min read